Cambridge University Hospitals NHS Foundation Trust

SAS unveils software as a service products for rapid AI application development

Retrieved on: 
Tuesday, September 12, 2023
Cloud, Data management, Visual Studio Code, Software as a service, Project Jupyter, Language, Wind, SAS, Organization, TypeScript, Cambridge University Hospitals NHS Foundation Trust, Patient, Algorithm, AI, Environment, News, Biopsy, Satellite navigation device, Software, React, Viya, Python

LAS VEGAS, Sept. 12, 2023 /PRNewswire/ -- SAS EXPLORE -- SAS, the leader in AI and analytics, has revealed expanded capabilities to its SAS® Viya® flagship data, AI and analytics platform.

Key Points: 
  • New SaaS products for data scientists and developers bring the power and productivity of SAS Viya to applications.
  • "We are constantly evolving the SAS Viya ecosystem with products to meet the emerging needs of data scientists and developers – for increased productivity and faster innovation."
  • An on-ramp to experience SAS Viya, SAS Viya Workbench also provides flexibility in the development environment with plans to include three clients – Jupyter Notebook, Visual Studio Code and SAS® Enterprise Guide®.
  • SAS App Factory – a rapid application development environment for creating fit-for-purpose, AI-driven applications.

Patient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge

Retrieved on: 
Tuesday, September 12, 2023
Cleveland Clinic, Mayo Clinic, Partnership, Crohn's disease, Bureau of Oceans and International Environmental and Scientific Affairs, Education, Inflammatory Bowel Diseases, Takeda, IBD, Health, Quality of life, Medicine, Research, Addenbrooke's Hospital, Harvard Medical School, Inflammatory bowel disease, Organization, Cambridge University Hospitals NHS Foundation Trust, Patient, Ulcerative colitis, Knowledge, Hospital, Ecosystem, CUH, Northwestern University, Addenbrooke, Pharmaceutical industry, Nursing

TORONTO, Sept. 12, 2023 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce two winners of the 2023 Takeda Canada Digital Health Innovation Challenge , a competition to identify and support innovative digital health solutions to improve patient outcomes and experiences.

Key Points: 
  • TORONTO, Sept. 12, 2023 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce two winners of the 2023 Takeda Canada Digital Health Innovation Challenge , a competition to identify and support innovative digital health solutions to improve patient outcomes and experiences.
  • This year's challenge winners are two patient-led organizations with disruptive digital solutions aimed at improving the patient journey in Inflammatory Bowel Disease (IBD), the most common forms being Ulcerative Colitis and Crohn's Disease.
  • Ayble Health is an all-in-one virtual gastroenterology platform that helps digestive disease patients, including those with inflammatory bowel disease, find long-term relief and control over their symptoms.
  • Partnering with Takeda Canada will help us empower more patients, transform their journey, and improve overall disease management."

Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 28, 2023
Pancreatic cancer, Restart, SCC, Medical school, Jewish General Hospital, D&O, Alpha, Symantec Endpoint Protection, Marketing, Clinical trial, Skin, Israel Land Authority, Head, G&A, Toxicity, Neck, Trial of the century, Liver cancer, Manager, Cambridge University Hospitals NHS Foundation Trust, Patient, General Hospital, PMDA, Financial result, Carcinoma, Addenbrooke's Hospital, Itch, McGill University, Financial toxicity, Vulva, Safety, D, Pharmaceutical industry, Nursing, Cryptocurrency, Medicine

JERUSALEM, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported second quarter 2023 financial results and provided a corporate update.

Key Points: 
  • JERUSALEM, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported second quarter 2023 financial results and provided a corporate update.
  • Alpha Tau expects to develop the land toward a future standalone global headquarters and lead manufacturing site, including significantly expanded areas for Alpha DaRT manufacturing, staff, and R&D facilities.
  • Targeting recruitment in the Canadian liver cancer feasibility trial to begin in the second half of 2023.
  • Planned submission of Alpha DaRT pivotal trial results in head and neck SCC to Japan’s regulatory authority, PMDA in the second half of 2023, for potential marketing authorization.

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Retrieved on: 
Thursday, August 10, 2023
DNA, Partnership, University, PD, Cancer research, Health care, MSS, University of Cambridge, Clinical trial, Cancer, Pharmacokinetics, Cancer Research UK, Head, Innovation, Toxicity, Immunotherapy, Neck, ECMC, PGE2, Neoplasm, GPCR, Cambridge University Hospitals NHS Foundation Trust, Patient, Colorectal cancer, Immune system, Drug development, CDD, EP4, Phase, Therapy, Environment, Tumor microenvironment, MHRA, Pharmaceutical industry, Vaccine

HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4).

Key Points: 
  • HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4).
  • In cancer, PGE2 acts in the tumor microenvironment to trigger cancer cells to evade the immune system.
  • Phase IIa of the trial will expand the optimal combination dose in up to four cohorts in specified cancer indications.
  • Sosei Heptares holds a license to the results generated under the trial to continue the clinical development and commercialization of HTL0039732.

GigXR and DICOM Director Debut Three-Dimensional Medical Imagery Learning Using Holograms of CT Scans and MRIs

Retrieved on: 
Thursday, August 3, 2023
Software, Hardware, Training, Medical Devices, Technology, Hospitals, University, Health Technology, Education, Photography, Surgery, Health, Gig, Heart, CT, Miami Dade College, University of Michigan, Defense, Nursing, Ursuline College, Basic life support, Catalog, Anatomy, Teaching, 3D, Pathology, Cambridge University Hospitals NHS Foundation Trust, DICOM, Android, Multimedia, Research, Google Images, IOS, Lung, MRI, Hospital, MD, Advanced cardiac life support, Respiratory disease, Department of Defense Serum Repository, NHS foundation trust, Reading, Kidney, Neurology, Diagnosis, XR, CUH, Cadaver, Injury, ANIMA, Medical imaging, Tutoring, Elsevier

The new application renders a complete set of hyper-realistic 3D medical imagery derived from MRI and CT scans for use in teaching, training, and simulation.

Key Points: 
  • The new application renders a complete set of hyper-realistic 3D medical imagery derived from MRI and CT scans for use in teaching, training, and simulation.
  • This empowers nursing and medical schools, hospitals, and the Department of Defense with the all-new ability to leverage holographic medical imagery in anatomy and pathophysiology curricula.
  • I also saw firsthand the need for better imaging technology,” said David Pearlstone, MD, CEO at DICOM Director.
  • With DICOM XR Library, learners can make a likely diagnosis of the patient prior to reviewing the corresponding 3D medical imagery.

Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 23, 2023
Pancreatic cancer, Restart, Rat, Medical school, Jewish General Hospital, Alpha, Symantec Endpoint Protection, Marketing, Clinical trial, Skin cancer, Skin, Head, G&A, Toxicity, Lung, Liver cancer, Ministry, Environmental protection, Cambridge University Hospitals NHS Foundation Trust, Patient, JAMA Network Open, General Hospital, PMDA, Carcinoma, Addenbrooke's Hospital, Financial result, McGill University, Biophysical environment, Mouse, Alpha Sigma Tau, Vulva, Health Canada, Pharmaceutical industry, Dietary supplement, Nursing, Cryptocurrency, Medicine

- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March -

Key Points: 
  • - Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March -
    - Received Health Canada approval in March to initiate a liver cancer feasibility trial, with recruitment targeted to begin mid-year -
    JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2023 financial results and provided a corporate update.
  • In parallel, we are preparing for potential future product launches by advancing our commercial planning activities and solidifying our supply chain.
  • Alpha Tau remains adequately capitalized to support all of these programs over the coming years," he concluded.
  • Planned submission of Alpha DaRT pivotal trial results in head and neck cancer to Japan’s regulatory authority, PMDA in the second half of 2023, for potential marketing authorization.

Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

Retrieved on: 
Wednesday, May 17, 2023
Alpha Sigma Tau, Alpha, Necrosis, RECIST, Pancreas, Cambridge University Hospitals NHS Foundation Trust, Breast, Brain, Lung, FRCR, MD, Patient, Lymph, Addenbrooke's Hospital, Neoplasm, Vulva, MRCP, Safety, Disease, Pharmaceutical industry, MBBS

The study will assess the safety and feasibility of using the Alpha DaRT by measuring the treatment-related adverse events in the 6-month follow-up period.

Key Points: 
  • The study will assess the safety and feasibility of using the Alpha DaRT by measuring the treatment-related adverse events in the 6-month follow-up period.
  • Alpha Tau CEO Uzi Sofer commented, “The initiation of this trial is a perfect example of how Alpha Tau is forging ahead in our strategy to address clinical indications of high unmet medical need.
  • We are hopeful that treatment with the novel and promising Alpha DaRT may offer better outcomes to these patients with such a challenging disease.
  • We appreciate the support from Alpha Tau Medical Ltd. and the CCTU-Cancer Theme for opening this trial and for securing a straightforward procedure for Alpha DaRT insertion into the cancerous lesion.”

Cambridge University Hospitals Expands Virtual Care Program with Masimo W1™

Retrieved on: 
Monday, May 8, 2023
Medical Devices, Hospitals, Health Technology, Telemedicine, Virtual Medicine, Health Insurance, Biometrics, Biotechnology, Managed Care, General Health, Health, National Health Service, Eye, Cambridge University Hospitals NHS Foundation Trust, ECG, Multimedia, MASI, Patient, Virtual Hospital, History of the National Health Service (England), NHS, FDA, Nursing, Hospital, Masimo

Masimo (NASDAQ: MASI) today announced that Cambridge University Hospitals NHS Foundation Trust, U.K. is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicine programs.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that Cambridge University Hospitals NHS Foundation Trust, U.K. is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicine programs.
  • We are excited for Cambridge clinicians and patients.”
    Cambridge University Hospitals NHS Foundation Trust launched its virtual ward program in 2022, as part of a National Health Service (NHS) England telehealth initiative designed to promote earlier patient discharge to the home.
  • Dr. Iain Goodhart, Clinical Director of the Virtual Hospital Program at Cambridge University Hospitals NHS Foundation Trust, commented, “Masimo W1 will help us expand our Virtual Hospital program by offering continuous monitoring of oxygen saturation and pulse rate, as well as ECG spot-checking, in a comfortable, easy to use watch.
  • We’re excited to incorporate Masimo W1 into our telehealth practices.”
    Masimo W1 for use in medical applications is pending FDA clearance in the U.S.

GigXR Awarded Air Force SBIR Phase II Contract to Develop Extended Reality (XR) Simulation Training for Department of the Air Force

Retrieved on: 
Wednesday, April 26, 2023
Technology, Contracts, Health Technology, Software, Government Technology, Training, General Health, Health, Education, Defense, Gig, Forward observers in the U.S. military, Checklist, Partnership, Miami Dade College, University, Bleeding, USAF, Nursing, Ursuline College, University of Leeds, Basic life support, SBIR, Anatomy, University Hospitals Cleveland Medical Center, Federal, Strategic planning, Explosion, Acquisition, Advanced cardiac life support, Patient, Respiratory disease, Gunshot, To Market, to Market (M*A*S*H), TCCC, Neurology, Injury, Cambridge University Hospitals NHS Foundation Trust, Phase, CUH, United States Air Force, ANIMA, BD, 68th Medical Group (United States), Elsevier

GigXR, Inc. , a global provider of holographic healthcare training, announced today that it has received a second Phase II Small Business Innovative Research (SBIR) contract to develop holographic simulation training for the 354th Medical Group United States Air Force (USAF) based out of Eielsen, Alaska.

Key Points: 
  • GigXR, Inc. , a global provider of holographic healthcare training, announced today that it has received a second Phase II Small Business Innovative Research (SBIR) contract to develop holographic simulation training for the 354th Medical Group United States Air Force (USAF) based out of Eielsen, Alaska.
  • GigXR will create high-stress, safe-to-fail situations that incorporate sounds, such as gunshots, explosions and helicopters overhead, to better mimic the experience of combat care.
  • “We are always extremely proud whenever we get to build something for the U.S. Military,” said Jared Mermey, CEO at GigXR.
  • “The mixed reality healthcare training that GigXR delivers is built to better prepare for what might be seen in the field.

An innovation partner to clients in challenging times -- PA Consulting reports on healthy performance in 2022 with growth of 96 percent over five years

Retrieved on: 
Thursday, April 20, 2023
Industrial Designers Society of America, Workforce, Uncertainty, Organic, Insurance, Plastic, Learning, Life, Diabetes, Face, Lasker-Koshland Special Achievement Award in Medical Science, Defence Science and Technology Laboratory, Pret, Cambridge University Hospitals NHS Foundation Trust, Woman, Microsoft, Wind, PA Consulting Group, YOY, IDSA, Community, Manger, Patient, Backbone One, US Wind, Engineering, Military science, Working Families Party, Coffee, Growth, Nike, National Energy Technology Laboratory, Arrhythmia, Industrial, Neurodiversity, Social mobility, Gjensidige, Cryptocurrency, Pharmaceutical industry, Sales, Video game, Nursing, Industrial design, Retail, Management, Logitech, STEM

Launched The PA Foundation , committing to disbursing £10 million over five years, with over £1.2 million donated to 20 charities.

Key Points: 
  • Launched The PA Foundation , committing to disbursing £10 million over five years, with over £1.2 million donated to 20 charities.
  • In the face of constant change and uncertainty in the world, clients are seeking a partner who can create opportunity from complexity.
  • PA strengthened its expert ranks with more than 1,300 new colleagues, including growing its partner numbers by 52, and awarding 815 promotions.
  • In its 2022 Ingenuity Review, PA identifies six global shifts, which will create new and exciting opportunities for clients.